Compare LCII & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCII | BEAM |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | LCII | BEAM |
|---|---|---|
| Price | $126.76 | $29.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $102.40 | $48.09 |
| AVG Volume (30 Days) | 230.4K | ★ 1.4M |
| Earning Date | 02-10-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 38.80 | N/A |
| EPS | ★ 7.12 | N/A |
| Revenue | ★ $3,992,455,000.00 | $55,701,000.00 |
| Revenue This Year | $10.93 | N/A |
| Revenue Next Year | $4.29 | $26.52 |
| P/E Ratio | $17.75 | ★ N/A |
| Revenue Growth | ★ 5.74 | N/A |
| 52 Week Low | $72.31 | $13.53 |
| 52 Week High | $126.56 | $35.25 |
| Indicator | LCII | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 73.52 | 63.38 |
| Support Level | $122.53 | $26.25 |
| Resistance Level | $125.00 | $30.50 |
| Average True Range (ATR) | 2.45 | 1.49 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 95.59 | 68.91 |
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.